"Health wise I am feeling great. I am a big supporter of trials - it allows new treatments and drugs to be brought in.”
A study of active surveillance, aspirin and vitamin D in men with prostate cancer (PROVENT)
This study was for men who were having regular monitoring for prostate cancer. It was open to men who had
This trial was open for people to join between 2016 and 2017. The team published the results in 2022.
More about this trial
This means you don’t have treatment straight away. Your doctor keeps a close eye on you to check for any signs that the cancer is growing. If it does you and your doctor can decide which treatment is best for you.
Research suggests that having aspirin and vitamin D can stop cancer from growing and changing.
This was a
- how willing men are to take part
- how well this treatment works for prostate cancer that has a low risk of growing or spreading
Summary of results
The team found that this type of trial was acceptable and safe to do.
This was a feasibility study. 130 men met the conditions to take part in the trial. Of these 104 men decided to take part.
It was a
Of the 104 men:
- 17 men had 300mg of aspirin and vitamin D
- 16 men had 300mg of aspirin and a vitamin D dummy drug
- 19 men had 100mg of aspirin and vitamin D
- 18 men had 100mg of aspirin and a vitamin D dummy drug
- 16 men had an aspirin dummy drug and vitamin D
- 18 men had an aspirin dummy drug and a vitamin D dummy drug
The study was set up to find out if it was possible to run a larger trial. This suggests that running a larger trial would be possible.
The team looked at the percentage of men who took their medication as directed. They found that 89 out of every 100 men (89%) did so during the study.
They were able to look at how well the treatment had worked in 76 of the men who took part. After a year they found that the:
- cancer didn’t get worse in 41 men
- cancer did get worse in 33 men
For 2 of the men the information wasn't available.
During the study 18 men decided to stop taking part in the study:
- 9 decided to have radiotherapy or surgery to remove their tumour
- 7 stopped due to reasons not related to their prostate cancer or treatment
- 2 men stopped due to side effects. For 1 man it was a very serious side effect.
In total there were 11 side effects. Of these 6 were not serious and 5 were.
Bleeding from the back passage was one of the serious side effects. This occurred twice in 1 man. His doctor thought the treatment caused it. He was taking 100mg aspirin and a vitamin D tablet. He stopped taking the treatment and no longer took part in the study.
The team concluded that their feasibility study showed that it was acceptable and safe to do a trial like this. They noted that another similar trial was to open using a different type of drug.
They said that researchers need to do a larger
More detailed information
There is more information about this research in the reference below.
Please note, this article is not in plain English. It has been written for healthcare professionals and researchers.
Eoin Dinneen, Gregory L. Shaw and others
BJUI Compass. 2022. Volume 3. Pages 458–465.
Where this information comes from
We have based this summary on the information in the article above. This has been reviewed by independent specialists (
How to join a clinical trial
Professor Greg Shaw
Barts and the London Charity
Experimental Cancer Medicine Centre (ECMC)
Queen Mary University of London